Descripción de la empresa
Chemed Corporation operates as a significant provider of hospice and palliative care services within the United States, utilizing a comprehensive network that includes physicians, registered nurses, home health aides, social workers, and volunteers to support patients primarily across the country. The entity functions within the broader Healthcare sector, specifically specializing in the Medical Care Facilities industry, which denotes a focus on delivering essential end-of-life care rather than acute medical treatment or pharmaceutical manufacturing. The company demonstrates substantial scale with a market capitalization of $5.20 billion and generates annual revenue totaling $2.53 billion, supported by a workforce of 15,811 employees. These valuation and revenue figures indicate that Chemed Corporation holds a considerable position within its niche, reflecting a mature business model that commands a multi-billion dollar market presence while employing a large labor force to deliver sensitive care services.
Salud financiera
Chemed Corporation reported a trailing twelve-month revenue of $2.53 billion, with a corresponding net income of $265.24 million and an EBITDA of $404.40 million, illustrating the operational scale required to sustain its service network. The gap between the $2.53 billion in revenue and the $265.24 million in net income reveals a significant cost structure, where operating expenses, including labor and overhead, consume approximately 89.5% of total revenue before reaching the bottom line. The company generated free cash flow of $246.01 million, which provides essential financial flexibility for maintaining its extensive facility network and managing the high fixed costs inherent in the medical care facilities industry. Profitability analysis shows a gross margin of 32.5%, indicating the efficiency of core service delivery; an operating margin of 16.6%, which reflects the effectiveness of managing overhead and administrative costs; and a profit margin of 10.5%, representing the final earnings available to shareholders after all expenses. Regarding liquidity and leverage, the company holds $74.52 million in cash against $143.76 million in total debt, resulting in a debt-to-equity ratio of 14.68, which suggests a leveraged balance sheet typical for capital-intensive healthcare operations. The current ratio stands at 1.05, indicating that the company possesses slightly more current assets than current liabilities, thereby signaling a tight but manageable short-term liquidity position. Furthermore, the return on equity is 25.3% and the return on assets is 13.4%, metrics that collectively reveal how effectively management utilizes shareholder capital and total assets to generate profits within a highly regulated environment.
Evaluación de valoración
The valuation metrics for Chemed Corporation show a trailing P/E ratio of 20.08 and a forward P/E of 13.85, where the significant difference between these two figures implies that the market expects a substantial expansion in earnings per share in the coming year to justify the lower forward multiple. The price-to-book ratio is recorded at 5.16, which indicates that the stock trades at a significant premium over its tangible book value, reflecting intangible assets such as brand reputation and proprietary networks in the hospice sector. Alternative valuation measures include a price-to-sales ratio of 2.06 and an EV/EBITDA of 12.72, suggesting that investors are willing to pay a premium for the company's revenue generation and earnings power relative to its enterprise value. The stock's recent trading range is defined by a 52-week high of $623.61 and a 52-week low of $365.25, providing context for the current market sentiment and volatility within the Healthcare sector. The beta value is 0.46, which indicates that the stock exhibits low price volatility relative to the broader market, moving less than half as much as the overall index during periods of market fluctuation.
Growth & Income
Regarding growth dynamics, the company experienced a revenue growth rate of -0.1% year-over-year and an earnings growth rate of -9.1% year-over-year, indicating that earnings are contracting at a much faster pace than the already stagnant revenue stream, which points to potential margin compression or cost pressures. As a dividend payer, Chemed Corporation offers a dividend yield of 0.6% with a payout ratio of 12.0%, a low payout figure that suggests the company retains the majority of its earnings for reinvestment or debt reduction rather than distributing high cash returns to shareholders. The sustainability of the dividend is reinforced by the low payout ratio, ensuring that the distribution remains secure even amidst the recent decline in reported earnings. The overall growth and income profile characterizes Chemed Corporation as a mature, low-volatility utility-like stock in the healthcare space that currently prioritizes capital preservation and operational stability over aggressive expansion or high dividend growth.